Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-on study of lomitapide in homozygous familial hypercholesterolemia
2010-023742-79Phase 3Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lomitapide in homozygous familial hypercholesterolemia (HoFH), sponsored by Aegerion Pharmaceuticals. Primary endpoints: Percent change in LDL-C at Week 48 and Lipid and lipoprotein parameters. Started Feb 2011; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2010-023742-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023742-79.